These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10338885)

  • 21. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 May; 67(90):31123-5. PubMed ID: 12001971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human cells, tissues, and cellular and tissue-based products; donor screening and testing, and related labeling. Interim final rule; opportunity for public comment.
    Food and Drug Administration, HHS
    Fed Regist; 2005 May; 70(100):29949-52. PubMed ID: 15915582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license--FDA. Proposed rule.
    Fed Regist; 1998 Jul; 63(147):40858-71. PubMed ID: 10181717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices--FDA. Final rule; amended economic analysis statement.
    Fed Regist; 1998 Jun; 63(104):29552-90. PubMed ID: 10179863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical device reporting: the US final rule.
    Donawa ME
    Med Device Technol; 1996 Mar; 7(2):14-6, 18, 20-1. PubMed ID: 10159867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule.
    Fed Regist; 1984 Aug; 49(171):34448-51. PubMed ID: 10299643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Foreign establishment registration and listing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Nov; 66(228):59138-61. PubMed ID: 11776289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Registration of food facilities under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(190):57505-9. PubMed ID: 16200686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date; reopening of administrative record. Food and Drug Administration, HHS. Final rule; delay of effective date; reopening of administrative record.
    Fed Regist; 2000 May; 65(86):25639-41. PubMed ID: 11010689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood vessels recovered with organs and intended for use in organ transplantation. Direct final rule.
    Food and Drug Administration, Health Resources and Services Administration, (HHS)
    Fed Regist; 2006 May; 71(92):27606-10. PubMed ID: 16696153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skin protectant drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(107):33362-81. PubMed ID: 12785379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beverages: bottled water. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Mar; 68(41):9873-82. PubMed ID: 12625359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of Salmonella enteritidis in shell eggs during production, storage, and transportation. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(130):33029-101. PubMed ID: 19588581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 1999 May; 64(93):26282-7. PubMed ID: 10558530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); companion document to direct final rule. Food and Drug Administration, HHS. Proposed rule.
    Fed Regist; 1999 May; 64(93):26344-8. PubMed ID: 10558531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical devices; preemption of state product liability claims--FDA. Correction.
    Fed Regist; 1997 Dec; 62(242):66179. PubMed ID: 10179302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.